AI Article Synopsis
- Metallothionein (MT) isoforms, specifically MT1 and MT2, have not been previously studied in papillary thyroid cancer (PTC), leading researchers to investigate their expression in KAT5 cells.
- The study found that cadmium induced eight functional MT isoforms in KAT5 cells, with elevated calcium and activated ERK1/2 signaling necessary for this expression.
- Blocking calcium or ERK1/2 pathways halted the expression of MT isoforms and altered cell cycle progression, suggesting that these isoforms facilitate the transition from the G0/G1 phase to the G2-M phase in papillary thyroid cancer.
Article Abstract
Metallothionein (MT) isoforms have not been studied in papillary thyroid cancer. We examined how the functional MT1 and MT2 isoforms were expressed in papillary thyroid cancer (KAT5) cells. We demonstrated that KAT5 cells expressed eight functional MT1 and MT2 isoforms induced by cadmium. Elevated calcium and activated ERK1/2 predated MT expression. The inhibition of either calcium or ERK1/2 significantly blocked the isoform expression. The induction of these isoforms accompanied an increased progression of cell cycle from G0/G1 to G2-M. The alternation in cell cycle disappeared when the expression of MT isoforms was blocked by calcium inhibitor or ERK1/2 inhibitor. Collectively, KAT5 cells express eight functional MT1 and MT2 isoforms in a pathway controlled by calcium and ERK1/2. The elevation of the MT isoforms contributes to the decreased G0/G1 but increased G2-M phase. These results reveal a novel pathway for the expression of the functional MT in papillary thyroid cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mce.2008.12.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Influence of Body Mass Index on the Clinicopathological Features of Papillary Thyroid Carcinoma in a Chinese Population.
Metab Syndr Relat Disord
January 2025
NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China.
Previous studies suggested a relationship between obesity and a high risk of thyroid cancer. However, the association between high body mass index (BMI) and the aggressiveness of papillary thyroid carcinoma (PTC) is controversial. In this study, we aimed to investigate the impact of excess BMI on histopathologic aggressiveness of PTC in a Chinese population.
View Article and Find Full Text PDFLong noncoding RNA FAM111A-DT promotes aggressiveness of papillary thyroid cancer via activating NF-κB signaling.
J Endocrinol Invest
January 2025
Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Purpose: Long noncoding RNAs (lncRNAs) play crucial regulatory roles in the tumorigenesis and progression of various cancers. However, the functional roles of lncRNAs in papillary thyroid cancer (PTC) remain unclear. In this study, we investigated the functional role of the lncRNA FAM111A-DT in PTC progression and the underlying mechanisms.
View Article and Find Full Text PDFLetter to the Editor "Ten-Year Outcomes of Radiofrequency Ablation for Locally Recurrent Papillary Thyroid Cancer".
Korean J Radiol
January 2025
Department of Radiology, Prof. Dr. Cemil Tascioglu City Hospital, University of Health Sciences, Istanbul, Türkiye.
Diagnostic performance of dual-energy computed tomography (DECT) quantitative parameters for detecting metastatic cervical lymph nodes in patients with papillary thyroid cancer: A systematic review and meta-analysis.
Eur J Radiol
January 2025
Department of Radiology, Hebei General Hospital, 348 Heping West Road, Shijiazhuang 050051, Hebei, China. Electronic address:
Purpose: This study systematically evaluated the diagnostic performance of dual-energy computed tomography (DECT) quantitative parameters in detecting cervical lymph node metastasis in patients with papillary thyroid cancer (PTC).
Method: We searched PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, and Wanfang Data databases for relevant original studies from database inception to March 2024. The quality of the included studies was evaluated using the QUADAS-2 tool.
Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types.
Geroscience
January 2025
Dept. of Bioinformatics, Semmelweis University, 1094, Budapest, Hungary.
Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), albiglutide (Tanzeum), dulaglutide (Trulicity), lixisenatide (Lyxumia, Adlyxin), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound), are widely used for the treatment of type 2 diabetes mellitus (T2DM) and obesity. While these agents are well known for their metabolic benefits, there is growing interest in their potential effects on cancer biology. However, the role of GLP-1R agonists in cancer remains complex and not fully understood, particularly across different tumor types.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!